| CAS ID: | 78919-13-8 |
| Molecular Formula: | C22H32O4 |
| Molecular Weight: | 360.5 g/mol |
| Monoisotopic Mass: | 360.2301 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | ILOPROST | CILOPROST | VENTAVIS | ZK 00036374 |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1 | See All |
| InChI Key: | HIFJCPQKFCZDDL-ACWOEMLNSA-N | |
| Smiles: | CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(=C/CCCC(=O)O)\C[C@H]12 | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 12368229 | Target ID | |
| Uniprot ID | Name | ||
| Model | Fibrosis Disease | Fibrosis | |
| Process I | |||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | Targeting cAMP/PKA signaling | ||
Trial Record 1
| ClinicalTrial ID | NCT00439543 | Disease | Pulmonary fibrosis |
| Phase | Phase 2,Phase 3 | Status | Unknown |
| First Received | February 23, 2007 | Last Verified | February 23, 2007 |
| Sponsor | Interstitial Lung Disease Study Group, Korea | ||
Trial Record 2
| ClinicalTrial ID | NCT00109681 | Disease | Pulmonary fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | May 3, 2005 | Last Verified | February 15, 2010 |
| Sponsor | Actelion | ||